Quince Therapeutics, Inc. (QNCX) Latest Company News

Oct 9, 2026, 12:08 UTC
Quince Therapeutics said Brendan Hannah resigned as chief operating officer, chief business officer and chief compliance officer, effective October 8, 2026, and appointed Keith Fandrick as his successor.
Oct 9, 2026, 12:08 UTC
Quince Therapeutics said Dirk Thye resigned as chief executive officer, chief medical officer and director, effective October 8, 2026, and appointed Brigette Roberts as chief executive officer.
Oct 9, 2026, 12:00 UTC
Quince Therapeutics, Inc. announced that its common stock will trade on NASDAQ, INC. under the symbol IRLA effective October 12, 2026.
Source:
- globenewswire.com
Oct 9, 2026, 12:00 UTC
Quince Therapeutics, Inc. named Brigette Roberts, M.D., as CEO, John Militello, CPA, as CFO, and Keith R. as COO.
Source:
- globenewswire.com
Oct 9, 2026, 12:00 UTC
Quince Therapeutics, Inc. relaunched as Quince Therapeutics, Inc., focusing on the clinical development of LAM-001 for pulmonary disease.
Source:
- globenewswire.com
Oct 2, 2026, 11:36 UTC
Quince Therapeutics, Inc. appointed Catherine Bonuccelli, Leone Patterson and James Valentine to its board of directors, succeeding departing directors June Bray, David Lamond and Christopher Senner.
Sep 14, 2026, 20:34 UTC
Quince Therapeutics, Inc. completed the sale of its subsidiary Quince Therapeutics SpA, certain AIDE-technology intellectual property, and all AIDE and eDSP machines and systems to Ayma Therapeutics, Inc. for $450,000 in cash.
Sep 8, 2026, 15:00 UTC
DelveInsight published a market research report on the sarcoidosis treatment market, forecasting growth through 2036 and highlighting emerging therapies.
Source:
- finanznachrichten.de
- prnewswire.com
Sep 4, 2026, 12:32 UTC
Quince Therapeutics, Inc. received a notice from Nasdaq on August 31, 2026, stating that it no longer complies with the minimum bid price requirement under Rule 5450(b)(1)(A) for continued listing on the Nasdaq Global Market, and the company is evaluating options to regain compliance and has applied to transfer to the Nasdaq Capital Market.
Aug 27, 2026, 00:00 UTC
Charles Ryan departed as President of Quince Therapeutics, Inc., effective September 8, 2026, and is eligible for severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023.
Aug 14, 2026, 12:00 UTC
Quince Therapeutics completed the acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to its pipeline.
Source:
- globenewswire.com
Aug 14, 2026, 00:00 UTC
Quince Therapeutics completed a private placement raising $115 million in gross proceeds, with potential additional proceeds of up to $83 million from warrant exercise.
Aug 14, 2026, 00:00 UTC
Quince Therapeutics reported a net loss of $75.5 million for Q2 2026, with diluted EPS of -$12.31.

QNCX

Quince Therapeutics said Brendan Hannah resigned as chief operating officer, chief business officer and chief compliance officer, effective October 8, 2026, and appointed Keith Fandrick as his successor.

Quince Therapeutics said Dirk Thye resigned as chief executive officer, chief medical officer and director, effective October 8, 2026, and appointed Brigette Roberts as chief executive officer.

Quince Therapeutics, Inc. announced that its common stock will trade on NASDAQ, INC. under the symbol IRLA effective October 12, 2026.

Quince Therapeutics, Inc. named Brigette Roberts, M.D., as CEO, John Militello, CPA, as CFO, and Keith R. as COO.

Quince Therapeutics, Inc. relaunched as Quince Therapeutics, Inc., focusing on the clinical development of LAM-001 for pulmonary disease.

Quince Therapeutics, Inc. appointed Catherine Bonuccelli, Leone Patterson and James Valentine to its board of directors, succeeding departing directors June Bray, David Lamond and Christopher Senner.

Quince Therapeutics, Inc. completed the sale of its subsidiary Quince Therapeutics SpA, certain AIDE-technology intellectual property, and all AIDE and eDSP machines and systems to Ayma Therapeutics, Inc. for $450,000 in cash.

DelveInsight published a market research report on the sarcoidosis treatment market, forecasting growth through 2036 and highlighting emerging therapies.

Charles Ryan departed as President of Quince Therapeutics, Inc., effective September 8, 2026, and is eligible for severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023.

Quince Therapeutics completed the acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to its pipeline.

Quince Therapeutics completed a private placement raising $115 million in gross proceeds, with potential additional proceeds of up to $83 million from warrant exercise.

Quince Therapeutics reported a net loss of $75.5 million for Q2 2026, with diluted EPS of -$12.31.